Peptides in 2TM · Semaglutide

Lau and colleagues described semaglutide’s discovery in 2015. The team included Jesper Lau, Paw Bloch, Thomas Kruse, Lotte Bjerre Knudsen and numerous colleagues. The film’s short list is not a sole-inventor attribution. Its company photograph shows Novo Nordisk’s Bagsværd campus in 2016, not the confirmed exact discovery laboratory.

Semaglutide is a modified GLP-1 analogue, not an antibody/Fc fusion. Its Aib substitution at position 8 improves resistance to DPP-4 degradation. A Lys26-linked C18 fatty diacid side chain promotes albumin binding and prolonged exposure. The molecular art illustrates reversible association, not an experimentally verified drug conformation or exact binding pose. The anatomical and tissue scenes are conceptual models, not patient imaging or quantitative physiology.

First U.S. approvals were Ozempic injection in 2017, Rybelsus oral semaglutide in 2019, and Wegovy injection in 2021. EU authorizations followed in 2018, 2020 and 2022 respectively. These historical milestones are distinct from current local availability. The product photos show later presentations, not original launch-year packaging.

Current U.S. labeling includes Ozempic tablets alongside the historical Rybelsus formulation, and Wegovy tablets alongside Wegovy injection. Indications differ by formulation, age and jurisdiction. Not every diabetes, cardiovascular, kidney, weight-management or liver indication applies to every presentation. The film does not establish automatic interchangeability or recommend a dose.

Published research supports SNAC-assisted semaglutide absorption through the stomach near the tablet. SNAC is not a permanent protective shell around every molecule, and the visualization does not depict holes in the stomach wall. Administration conditions matter; consult the relevant product label.

SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity, without diabetes. Once-weekly injectable semaglutide 2.4 mg was compared with placebo alongside standard care. The primary composite was cardiovascular death, nonfatal myocardial infarction (heart attack), or nonfatal stroke. Events occurred in 569/8,803 participants (6.5%) versus 701/8,801 (8.0%). The hazard ratio was 0.80 (95% confidence interval 0.72–0.90), with mean follow-up of 39.8 months. This is a 20% lower relative hazard of the composite, not a 20 percentage-point reduction, an identical benefit for each component, or an individual guarantee. It does not establish the same result for every dose, brand, formulation or patient population.

The film includes selected safety information. Gastrointestinal effects are common; important warnings include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, hypoglycemia with insulin or insulin secretagogues, hypersensitivity, retinopathy concerns and aspiration during anesthesia or deep sedation. U.S. boxed warnings concern thyroid C-cell tumors observed in rodents; relevance to humans is unknown. Personal or family medullary thyroid carcinoma and MEN2 are contraindications. Pregnancy, breastfeeding and regional restrictions require the current local label.

• Lau and colleagues, Journal of Medicinal Chemistry, 2015: semaglutide discovery
• Buckley and colleagues, Science Translational Medicine, 2018: SNAC-assisted stomach absorption
• Lincoff and colleagues, NEJM, 2023: SELECT cardiovascular outcomes
• Current U.S. Ozempic injection prescribing information
• Current U.S. oral semaglutide labeling: Rybelsus and Ozempic tablets
• Current U.S. Wegovy injection and tablet prescribing information
• EMA: Ozempic
• EMA: Rybelsus
• EMA: Wegovy
• Novo Nordisk development account; identified as a company source

Images, music & reuse rights

Campus photograph: News Øresund / Johan Wessman, Novo Nordisk headquarters, Denmark, June 8, 2016, CC BY 3.0; cropped, shaded, titled and animated. No endorsement implied.

Authentic product photographs are from Novo Nordisk’s Ozempic media kit and Wegovy media kit. The manufacturer’s media library permits noncommercial use for reporting or research related to Novo. This does not establish monetized-video or commercial-advertising rights; additional permission or alternative imagery is required for those uses. The Rybelsus historical card is text-based. Later product presentations are not represented as original approval-year packaging, and the newer high-dose Wegovy presentation pictured was not the dose studied in SELECT.

Six new AI-created artworks depict a peptide, albumin association, anatomical torso, gastric absorption, heart and analytical laboratory. They are conceptual illustrations rather than authentic laboratory photographs, patient scans, microscopy or validated drug structures. Narration and music are synthetic; Montserrat is used under the SIL Open Font License.

Source verification is distinct from scientific assessment or personal human review. No independent human scientific review is claimed. Educational information, not medical advice. WPF does not sell peptides. Suggest a correction.